A federal jury in Boston found Takeda Pharmaceutical liable for approximately $885 million in damages after determining the company delayed generic competition for its constipation drug Amitiza through an unlawful anticompetitive agreement. The plaintiffs included insurers, wholesalers, pharmacies, health funds, and major retailers such as CVS Health and Walgreens, which argued they paid inflated prices because lower-cost generic alternatives were kept off the market.
The case focused on a 2014 settlement between Takeda, Sucampo Pharmaceuticals, and Par Pharmaceutical after Par challenged Amitiza patents while seeking FDA approval for a generic version. Jurors agreed with plaintiffs that the arrangement effectively paid Par to delay launching a competing product until 2021. Plaintiffs claimed the deal was worth roughly $210 million through a profit-sharing arrangement tied to an authorized generic version of the drug.
The ruling is significant for insurers and claims professionals monitoring pharmaceutical litigation trends and healthcare cost exposure. Federal antitrust law allows most damages in the case to be automatically tripled, meaning Takeda's liability could exceed $2.4 billion. Large verdicts tied to drug pricing and competition disputes can affect health insurers, pharmacy benefit managers, and employer-sponsored health plans through higher claim costs and reserve pressures.
The verdict also marks the first successful jury verdict for plaintiffs in a pharmaceutical pay-for-delay class action since the 2013 U.S. Supreme Court decision allowing such agreements to be challenged under antitrust law. Earlier jury trials in similar cases ended in defense wins, making this decision a closely watched development for pharmaceutical manufacturers, insurers, and litigation specialists assessing future exposure tied to patent settlements and generic drug competition.
Takeda said it plans to appeal, arguing legal and evidentiary errors occurred during the five-week trial. The company also stated it is evaluating the financial impact the verdict may have on its prior fiscal year statements.
